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to sPTV. The mean V20 values was 7.8% for dynamic tracking 
SBRT (tV20) and 8.1% for static SBRT (sV20), corresponding to 
an average reduction of 11.2 ± 5.9% (p = 0.016) in the tV20 
compared to sV20. 
Conclusions: This study demonstrates that lung SBRT with 
DTT reduces treatment volumes and dose to normal lung 
tissue. Further clinical outcome data are required to validate 
these findings.  
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Purpose/Objective: Radiotoxicity during radiotherapy of lung 
cancer may be misdiagnosed as pneumonia or respiratory 
tract infections which prevents the patients from getting 
optimal treatment. We evaluated changes of three 
inflammation-associated cytokines in patients undergoing 
radiotherapy for non-small cell lung cancer (NSCLC) to 
establish changes of their levels and evaluate which of the 
markers: Interleukin 6 (IL-6), Tumour necrosis factor-alpha 
(TNF-a) or Lipopolysaccharide-binding protein (LBP) are 
specifically affected by radiation dose received by the 
pulmonary and mediastinal structures rather than infection. 
Materials and Methods: In this pilot phase of the project we 
evaluated 29 patients treated for NSCLC by means of 
2.0Gy/daily schemes with total target doses in the range of 
60-74Gy. Cytokines were measured before start of treatment, 
on the day of reaching the total dose of 20Gy and at 40Gy. An 
age-matched control group of 8 individuals was used to 
establish differences in baseline cytokine levels. Data from 
the 40Gy time-point were correlated with histogram 
parameters of the radiotherapy protocol. ELISA kits were 
used for cytokine quantification (IL-6 and TNF-a by R&D, USA 
and LBP by Abnova, Taiwan). Arithmetical means were used 
for LBP, while geometrical means were used to represent 
results of IL-6 and TNF-a due to non-normal distribution of 
values. 
Results: Average age of the group was 64.61+/-6.57 years, 
majority of patients were male (18 vs 11). The group with 
NSCLC showed higher than controls baseline levels of IL-6 
(5.11+/-2.52 vs 2.18+/-2.19; p=0.02) and marginally higher 
TNF-a (17.94+/-1.16 vs 16.30+/-1.17; p=0.12). No such 
differences were seen in LPB levels (35.86+/-8.45 vs 32.69+/-
9.38; p=0.36). Levels of all three cytokines remained 
unchanged during treatment: IL-6 5.11+/-2.52; 4.59+/-1.86 
and 6.15+/-4.00 (p=0.25); TNF-a 17.94+/-1.16; 17.56+/-1.18 
and 19.88+/-1.74 (p=0.47); LBP 35.87+/-8.45; 35.72+/-7.58 
and 35.82+/-7.06 (p=0.36). However, at the 40Gy timepoint, 
positive, significant correlations were noted for LBP and lung 
volume subjected to 5Gy (r=0.52, p=0.01), 20Gy (r=0.41, 
p=0.049) and mean radiation dose planned for lung tissue 
(r=0.49, p=0.02, Figure 1). Neither IL-6 nor TNF-a showed 
such associations, hinting at the specificity of LBP reaction to 
lung irradiation. 
 
 
Conclusions: LBP levels correlate with radiation exposure of 
pulmonary tissue regardless of infectious causes and can be 
used for further studies on radiotoxicity in NSCLC patients. 
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Purpose/Objective: Patients with lung cancer undergoing 
radiotherapy (RT) are at risk of lung-related toxicity such as 
radiation pneumonitis (RP). It has been reported that RP 
occurs after initiation of radiotherapy for a wide range of 
doses in the normal lung tissue. In addition to RT, the effect 
of targeted therapy such as erlotinib on normal lung needs to 
be considered. Medical imaging may be employed for 
detection of normal tissue effects from RT and erlotinib. This 
